Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
FDA approves new medication for chronic weight management U.S
The major growth driver for this segment is the increasing focus on metabolic research on the cellular redox balance, where oxidized glutathione plays a pivotal role in assessing oxidative stress and cellular repair mechanisms
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Mix 1 to 2 mL of bacteriostatic water with the lyophilized BPC-157 powder
